76 patents
Page 2 of 4
Utility
FcRn Antibodies and Methods of Use Thereof
16 Feb 23
The present application features antibodies that bind to human neonatal Fc receptor (FcRn).
Leona E. Ling, Sucharita Roy, Nathaniel Washburn, Marilyn Kehry, David J. King, Anthony Manning, James Meador, III, Jan Hillson
Filed: 28 Apr 22
Utility
Antibodies Against Integrin Alpha 11 Beta 1
16 Feb 23
The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 (α11β1), as well as methods of making and using such antibodies.
Elma KURTAGIC, James W. MEADOR, III, Christopher BENEDUCE
Filed: 18 Dec 20
Utility
Method for Generating Speed Control Model, Vehicle Control Method and Apparatus
24 Nov 22
Disclosed in the present application are a method for generating a speed control model, a vehicle control method and an apparatus.
Yu CHEN
Filed: 5 Aug 22
Utility
Method and Apparatus for Determining Vehicle Speed Control Model Training Sample
24 Nov 22
Disclosed in the present disclosure are a method and an apparatus for determining a vehicle speed control model training sample.
Yu CHEN
Filed: 5 Aug 22
Utility
Method for Generating Lane Changing Decision-making Model, Method for Lane Changing Decision-making of Unmanned Vehicle and Electronic Device
17 Nov 22
Provided are a method for generating a lane changing decision-making model and a method and an apparatus for lane changing decision-making of an unmanned vehicle.
Tianyu SHI, Xu RAN
Filed: 16 Oct 20
Utility
ENGINEERED Fc CONSTRUCTS
25 Aug 22
The present disclosure relates to engineered IgG Fc constructs and uses thereof.
Carlos J. Bosques, Jonathan C. Lansing, Daniel Ortiz
Filed: 16 Nov 21
Utility
COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
25 Aug 22
The present disclosure relates to compositions and methods of engineered Fc-antigen binding domain constructs, where the Fc-antigen binding domain constructs include at least two Fc domains and at least one antigen binding domain.
Jonathan C. Lansing, Daniel Ortiz
Filed: 11 Jul 19
Utility
Methods For The Treatment Of Neurodegeneration
25 Aug 22
The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or a 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease.
Thomas E. Prod`Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
Filed: 9 May 22
Utility
Methods for the treatment of neurodegeneration
7 Jun 22
The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease.
Thomas E. Prod'Homme, Leona E. Ling, Carlos J. Bosques, Anthony Manning, Ganesh Kaundinya
Filed: 1 Nov 19
Utility
FcRn antibodies and methods of use thereof
31 May 22
The present application features antibodies that bind to human neonatal Fc receptor (FcRn).
Leona E. Ling, Sucharita Roy, Nathaniel Washburn, Marilyn Kehry, David J. King, Anthony Manning, James Meador, III, Jan Hillson
Filed: 31 Jul 17
Utility
Methods of Producing Ustekinumab
17 Mar 22
Methods of manufacturing an ustekinumab product with a target level of one or more glycans are described.
Ru Zang
Filed: 20 Dec 19
Utility
COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
3 Mar 22
Fc-antigen binding constructs having a CTLA-4 binding domain and two or more Fc domains are described as are methods for using such constructs.
Anthony Manning, Jonathan C. Lansing, Daniel Ortiz, Laura Rutitzky
Filed: 11 Jul 19
Utility
FcRn Antibodies and Methods of Use Thereof
3 Mar 22
The present invention features antibodies that bind to human neonatal Fc receptor (FcRn).
Leona E. Ling, Darrell Nix, Nicholas A. Cilfone
Filed: 13 Dec 18
Utility
Methods of Producing Ustekinumab
3 Feb 22
Methods of manufacturing an ustekinumab product with a target level of one or more glycans are described.
Ru Zang
Filed: 20 Dec 19
Utility
Methods for Measuring Consumption of Amino Acid N-Carboxyanhydrides during Manufacture of Glatiramer Acetate
27 Jan 22
Methods for assessing and/or selecting as suitable for commercial release glatiramer acetate, including assessing the consumption, and/or relative reaction kinetics of one or more the amino acid N-Carboxyanhydrides (NCAs) present during the first step of the polymerization reaction in the glatiramer acetate manufacturing process are provided.
Mani S. Iyer
Filed: 16 Aug 21
Utility
Engineered Fc constructs
11 Jan 22
The present disclosure relates to engineered IgG Fc constructs and uses thereof.
Carlos J. Bosques, Jonathan C. Lansing, Daniel Ortiz
Filed: 5 Jan 18
Utility
Treatment with Highly Silylated Igg Compositions
18 Nov 21
Compositions comprising a highly sialylated IgG preparation and methods for treating a patient using such preparations are described.
Santiago Arroyo, William Denney
Filed: 11 Oct 19
Utility
FCRN Antibody Compositions
4 Nov 21
This disclosure pertains to compositions comprising an anti-FcRn antibody, M281.
Zhongli ZHANG, Michael SHIFRIN, Nathaniel J. WASHBURN, Aneta LIWOSZ, Nasir KHAN
Filed: 19 Jul 19
Utility
Glycan Oxonium Ion Profiling of Glycosylated Proteins
28 Oct 21
Methods disclosed herein include an improved technique for comparing a glycosylation profile of a first protein (e.g., an innovator protein drug) with a glycosylation profile of a second protein (e.g., a corresponding biogeneric/biosimilar).
James Madsen, Victor Farutin
Filed: 17 Aug 17
Utility
Compositions and methods related to engineered Fc constructs
26 Oct 21
The present invention relates to engineered IgG Fc constructs and uses thereof.
Carlos J. Bosques, Jonathan C. Lansing, Daniel Ortiz, Laura Rutitzky, Nathaniel J. Washburn
Filed: 23 May 17